GRFS Grifols SA
Company Analysis
Latest News
🟢 Grifols rises 4.0% — Biotech Sector Rallies on Positive Clinical Data and Regulatory News
With Biotech (XBI) up 2.2%, this looks like a sector-led move rather than a company-specific surprise. The biotechnology sector, as measured by the XBI ETF,...
🟢 Grifols SA is trading 4.01% up in pre-market
GRFS is trading at $7.53, up 4.01% in pre-market.
Grifols SA Q2 2026 Earnings Preview: What Analysts Expect on September 28, 2026
Consensus estimates for Grifols SA anticipate Q2 2026 revenue of $2.07 billion and an EPS of $0.27, while the stock currently trades at $10.45 compared to an...
Grifols SA Q2 2026 Earnings Preview: What Analysts Expect on September 21, 2026
Analysts expect Grifols SA to report Q2 2026 revenue of approximately $1.95 billion and earnings per share of $0.27, with the stock currently trading near...
🟢 Grifols is trading 8.7% up in after-hours trading with no confirmed company-specific catalyst
Grifols is trading at $8.00, up 8.70% in after-hours trading despite no confirmed company-specific catalyst. - No confirmed September 15, 2026 announcement,...
Grifols SA Q2 2026 Earnings Preview: What Analysts Expect on September 14, 2026
For the second quarter of 2026, analysts expect Grifols SA to report consensus revenue of $2.16 billion and an EPS of $0.27, with the current stock price of...
Grifols SA Q2 2026 Earnings Preview: What Analysts Expect on September 07, 2026
Wall Street analysts expect Grifols SA to report Q2 2026 revenue of $2.23 billion and earnings of $0.27 per share, while the stock currently trades at $7.80...
Grifols SA Q2 2026 Earnings Preview: What Analysts Expect on August 31, 2026
Grifols is expected to report Q2 2026 revenue of $2.17 billion and an EPS of $0.27, with the stock’s current price of $8.25 trading significantly below the...
Grifols SA Q2 2026 Earnings Preview: What Analysts Expect on August 24, 2026
Grifols SA is expected to report Q2 2026 revenue of $2.17 billion and an EPS of $0.27, while the stock currently trades around $8.25—well below the average...
🟢 Grifols rises 5.0% — Biotech Sector Surges on Positive mRNA Cancer Vaccine Trial Results
With Biotech (XBI) up 3.7%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector, proxied by the XBI ETF, is trading...
Grifols SA Q2 2026 Earnings Preview: What Analysts Expect on August 17, 2026
Grifols SA is expected to post Q2 2026 revenue of $2.01 billion and EPS of $0.27, with its current share price of $8.45 sitting significantly under the $12.10...
Grifols SA Q2 2026 Earnings Preview: What Analysts Expect on August 10, 2026
For the second quarter of 2026, analysts anticipate Grifols to report a consensus revenue of $2.17 billion and an EPS of $0.27, while the current ADR price of...
Grifols SA Q2 2026 Earnings Preview: What Analysts Expect on August 03, 2026
Grifols is expected to report Q2 2026 revenue of $2.06 billion and EPS of $0.27, with the stock currently trading at $9.45 against an average analyst price...
🔴 Grifols is trading 4.4% down today on potential profit-taking
Grifols is trading at $7.84 (down 4.4%) today as the stock faces downward pressure despite a lack of fresh, company-specific headlines. • The move follows a...
Grifols Profits Surge 29%, Driven by Strong Biopharma Demand
Grifols reported a 28.7% increase in net profit to €227 million for the first half of 2026. Revenues rose 2.6% at constant currency to €3.57 billion. The...
🟢 Grifols is trading 4.25% up today on continued idiosyncratic strength
Grifols is trading at $8.34 (+4.25%) in pre-market, extending its upward momentum following a 3.23% gain on July 28. • The move appears driven by...
🟢 Grifols is trading 4.1% up today, defying broader biotech sector weakness
Grifols is trading 4.1% up at $8.07 on above-average intraday strength despite a lack of clear company-specific catalysts. • The move stands out as the...
Grifols SA Q2 2026 Earnings Preview: What Analysts Expect on July 27, 2026
Grifols is expected to report consensus revenue of $2.22 billion and an EPS of $0.28, with the stock currently trading at $7.61 compared to an average analyst...
🟢 Grifols is trading 4.2% up today amid broader risk-on sentiment
Grifols is trading at $7.58 (+4.20%) amid broader risk-on sentiment as the U.S. session continues. • The upward move appears to be taking place without a...
Grifols splits U.S. biopharma unit, seeking higher margins and independence
Grifols is reorganizing its global operations to grant subsidiaries greater financial and operational independence. The plan creates a standalone structure for...